vs
Idexx Laboratories（IDXX）与WEIS MARKETS INC（WMK）财务数据对比。点击上方公司名可切换其他公司
WEIS MARKETS INC的季度营收约是Idexx Laboratories的1.2倍（$1.3B vs $1.1B），Idexx Laboratories净利率更高（22.8% vs 2.5%，领先20.3%），Idexx Laboratories同比增速更快（14.3% vs 5.0%），Idexx Laboratories自由现金流更多（$326.3M vs $36.4M），过去两年Idexx Laboratories的营收复合增速更高（6.4% vs 4.7%）
IDEXX Laboratories是1983年成立的美国跨国企业，主营伴侣动物诊疗、畜禽养殖、水质检测、乳制品领域相关产品与服务的研发、生产及分销，总部位于缅因州韦斯特布鲁克，欧洲、中东及非洲地区分部设于荷兰霍夫多普。
魏斯市场（Weis Markets）是美国本土食品零售企业，总部位于宾夕法尼亚州森伯里。目前在宾夕法尼亚、马里兰、纽约、新泽西、西弗吉尼亚、弗吉尼亚、特拉华七个州运营200家门店，员工规模超2.3万人。
IDXX vs WMK — 直观对比
营收规模更大
WMK
是对方的1.2倍
$1.1B
营收增速更快
IDXX
高出9.2%
5.0%
净利率更高
IDXX
高出20.3%
2.5%
自由现金流更多
IDXX
多$289.9M
$36.4M
两年增速更快
IDXX
近两年复合增速
4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.3B |
| 净利润 | $248.2M | $32.0M |
| 毛利率 | 60.3% | 25.3% |
| 营业利润率 | 28.9% | 3.2% |
| 净利率 | 22.8% | 2.5% |
| 营收同比 | 14.3% | 5.0% |
| 净利润同比 | 14.8% | -5.1% |
| 每股收益（稀释后） | $3.09 | $1.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IDXXWMK
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $998.4M | $1.2B | ||
| Q4 24 | $954.3M | $1.2B | ||
| Q3 24 | $975.5M | $1.2B | ||
| Q2 24 | $1.0B | $1.2B | ||
| Q1 24 | $964.1M | $1.2B |
净利润IDXXWMK
| Q4 25 | $248.2M | $32.0M | ||
| Q3 25 | $274.6M | $16.9M | ||
| Q2 25 | $294.0M | $25.3M | ||
| Q1 25 | $242.7M | $19.5M | ||
| Q4 24 | $216.1M | $33.7M | ||
| Q3 24 | $232.8M | $24.5M | ||
| Q2 24 | $203.3M | $25.4M | ||
| Q1 24 | $235.6M | $22.4M |
毛利率IDXXWMK
| Q4 25 | 60.3% | 25.3% | ||
| Q3 25 | 61.8% | 24.7% | ||
| Q2 25 | 62.6% | 25.2% | ||
| Q1 25 | 62.4% | 24.8% | ||
| Q4 24 | 59.8% | 25.4% | ||
| Q3 24 | 61.1% | 24.6% | ||
| Q2 24 | 61.7% | 25.1% | ||
| Q1 24 | 61.5% | 24.9% |
营业利润率IDXXWMK
| Q4 25 | 28.9% | 3.2% | ||
| Q3 25 | 32.1% | 1.7% | ||
| Q2 25 | 33.6% | 2.5% | ||
| Q1 25 | 31.7% | 1.8% | ||
| Q4 24 | 27.4% | 3.3% | ||
| Q3 24 | 31.2% | 2.3% | ||
| Q2 24 | 26.3% | 2.6% | ||
| Q1 24 | 31.0% | 2.2% |
净利率IDXXWMK
| Q4 25 | 22.8% | 2.5% | ||
| Q3 25 | 24.8% | 1.4% | ||
| Q2 25 | 26.5% | 2.1% | ||
| Q1 25 | 24.3% | 1.6% | ||
| Q4 24 | 22.7% | 2.7% | ||
| Q3 24 | 23.9% | 2.1% | ||
| Q2 24 | 20.3% | 2.1% | ||
| Q1 24 | 24.4% | 1.9% |
每股收益（稀释后）IDXXWMK
| Q4 25 | $3.09 | $1.27 | ||
| Q3 25 | $3.40 | $0.69 | ||
| Q2 25 | $3.63 | $0.96 | ||
| Q1 25 | $2.96 | $0.73 | ||
| Q4 24 | $2.62 | $1.25 | ||
| Q3 24 | $2.80 | $0.91 | ||
| Q2 24 | $2.44 | $0.95 | ||
| Q1 24 | $2.81 | $0.83 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.1M | $214.2M |
| 总债务越低越好 | $450.0M | — |
| 股东权益账面价值 | $1.6B | $1.4B |
| 总资产 | $3.4B | $2.0B |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资IDXXWMK
| Q4 25 | $180.1M | $214.2M | ||
| Q3 25 | $208.2M | $177.6M | ||
| Q2 25 | $164.6M | $188.8M | ||
| Q1 25 | $164.0M | $337.9M | ||
| Q4 24 | $288.3M | $382.3M | ||
| Q3 24 | $308.6M | $381.2M | ||
| Q2 24 | $401.6M | $398.7M | ||
| Q1 24 | $397.4M | $397.5M |
总债务IDXXWMK
| Q4 25 | $450.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $617.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益IDXXWMK
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.6B | $1.3B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.4B | $1.4B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.6B | $1.4B | ||
| Q2 24 | $1.6B | $1.4B | ||
| Q1 24 | $1.6B | $1.4B |
总资产IDXXWMK
| Q4 25 | $3.4B | $2.0B | ||
| Q3 25 | $3.4B | $2.0B | ||
| Q2 25 | $3.3B | $1.9B | ||
| Q1 25 | $3.2B | $2.1B | ||
| Q4 24 | $3.3B | $2.1B | ||
| Q3 24 | $3.4B | $2.1B | ||
| Q2 24 | $3.4B | $2.1B | ||
| Q1 24 | $3.4B | $2.0B |
负债/权益比IDXXWMK
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.39× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $355.8M | $86.6M |
| 自由现金流经营现金流 - 资本支出 | $326.3M | $36.4M |
| 自由现金流率自由现金流/营收 | 29.9% | 2.8% |
| 资本支出强度资本支出/营收 | 2.7% | 3.9% |
| 现金转化率经营现金流/净利润 | 1.43× | 2.71× |
| 过去12个月自由现金流最近4个季度 | $1.1B | $4.8M |
8季度趋势，按日历期对齐
经营现金流IDXXWMK
| Q4 25 | $355.8M | $86.6M | ||
| Q3 25 | $402.3M | $59.2M | ||
| Q2 25 | $185.7M | $56.6M | ||
| Q1 25 | $238.0M | $4.9M | ||
| Q4 24 | $262.0M | $87.1M | ||
| Q3 24 | $220.1M | $25.8M | ||
| Q2 24 | $248.3M | $40.3M | ||
| Q1 24 | $198.6M | $34.2M |
自由现金流IDXXWMK
| Q4 25 | $326.3M | $36.4M | ||
| Q3 25 | $371.2M | $-4.7M | ||
| Q2 25 | $151.6M | $1.4M | ||
| Q1 25 | $207.9M | $-28.3M | ||
| Q4 24 | $232.8M | $33.7M | ||
| Q3 24 | $192.0M | $-16.5M | ||
| Q2 24 | $215.0M | $10.2M | ||
| Q1 24 | $168.3M | $-1.3M |
自由现金流率IDXXWMK
| Q4 25 | 29.9% | 2.8% | ||
| Q3 25 | 33.6% | -0.4% | ||
| Q2 25 | 13.7% | 0.1% | ||
| Q1 25 | 20.8% | -2.4% | ||
| Q4 24 | 24.4% | 2.7% | ||
| Q3 24 | 19.7% | -1.4% | ||
| Q2 24 | 21.4% | 0.9% | ||
| Q1 24 | 17.5% | -0.1% |
资本支出强度IDXXWMK
| Q4 25 | 2.7% | 3.9% | ||
| Q3 25 | 2.8% | 5.1% | ||
| Q2 25 | 3.1% | 4.5% | ||
| Q1 25 | 3.0% | 2.8% | ||
| Q4 24 | 3.1% | 4.3% | ||
| Q3 24 | 2.9% | 3.6% | ||
| Q2 24 | 3.3% | 2.5% | ||
| Q1 24 | 3.1% | 3.0% |
现金转化率IDXXWMK
| Q4 25 | 1.43× | 2.71× | ||
| Q3 25 | 1.47× | 3.50× | ||
| Q2 25 | 0.63× | 2.24× | ||
| Q1 25 | 0.98× | 0.25× | ||
| Q4 24 | 1.21× | 2.59× | ||
| Q3 24 | 0.95× | 1.05× | ||
| Q2 24 | 1.22× | 1.58× | ||
| Q1 24 | 0.84× | 1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
WMK
| Grocery | $1.0B | 80% |
| Pharmacy | $186.7M | 14% |
| Fuel Product | $66.5M | 5% |
| Services | $5.9M | 0% |
| Manufacturing | $2.2M | 0% |
